Drug Distribution, Biotransformation and Pharmacogenetic Variation

A rapid-revision synthesis connecting drug movement, apparent distribution, metabolism and patient-to-patient variation in drug response.

1. THE TOPIC IN ONE CONNECTED FLOW

After reaching the systemic circulation, a drug distributes between plasma and tissues. The extent of this movement determines its apparent volume of distribution and influences loading dose. The drug may then undergo biotransformation, mainly in the liver, while genetic variation and enzyme induction or inhibition can change its concentration, effect and toxicity.

Drug in Blood
Free + protein-bound fractions

→

Distribution
Blood flow, permeability, lipid solubility, ionization and binding

→

Apparent Vd
Small when plasma-restricted; large with extensive tissue distribution

→

Loading Dose
Target concentration × Vd ÷ bioavailability

→

Biotransformation
Mainly liver: Phase I and/or Phase II reactions

→

Enzyme Modulation & Genetics
Induction, inhibition and inherited enzyme variation

→

Clinical Response
Altered therapeutic effect, duration or toxicity

2. KEY CLINICAL CONNECTIONS

Low Albumin & Drug Effect

Reduced albumin
→
less binding of a highly protein-bound drug
→
increased free fraction
→
greater pharmacological effect or toxicity.

Distribution Barriers

Tight cerebral endothelial junctions
→
restricted entry of polar drugs
→
limited CNS penetration.

Placental transfer
→
fetal drug exposure may occur because the placenta is not an absolute barrier.

Enzyme Induction vs Inhibition

Induction
→
faster metabolism of an active substrate
→
lower concentration and reduced effect.

Inhibition
→
slower metabolism
→
increased concentration and toxicity risk.

3. AIM HIGH-YIELD INTEGRATION REVIEW

⭐ Free drug crosses membranes and reaches receptors, while reversible plasma protein binding acts as a temporary reservoir.

Blood flow and membrane permeability determine the rate of distribution; tissue and protein binding influence its extent.

⭐ Low plasma concentration despite substantial drug in the body
→
large apparent Vd
→
extensive tissue distribution.

Larger Vd at the same target concentration
→
larger loading dose; incomplete bioavailability further increases the required dose.

Phase I reactions such as oxidation, reduction and hydrolysis
→
functional modification; Phase II conjugation
→
greater polarity and easier elimination.

⭐ Biotransformation may inactivate an active drug, create an active metabolite, activate a prodrug or produce a toxic metabolite.

Genetic variation in metabolic enzymes
→
slow or rapid metabolism
→
differences in drug concentration, therapeutic response and toxicity.

⭐ Mechanism-based inhibition
→
enzyme converts the inhibitor into a reactive intermediate
→
enzyme becomes inactivated
→
recovery requires restoration of functional enzyme activity.

AIM Exam Trap: Increased metabolism does not necessarily reduce drug effect. If metabolism activates a prodrug or produces an active metabolite, enzyme induction may increase formation of the active compound; enzyme inhibition may reduce it.